Trial · NCT03596957
Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease
NCT03596957, Phase 4, Unknown, Lisbet Brandi
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease. Trials, record NCT03596957. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03596957
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease
- NCT number
- NCT03596957
- Status
- Unknown
- Phases
- Phase 4
- Enrollment
- 90 participants, estimated
- Lead sponsor
- Lisbet Brandi
- Conditions
- Autosomal Dominant Polycystic Kidney
- Interventions
- Tolvaptan
- First posted
- 2018-07-24
- Last updated
- 2018-11-26
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in total Kidney Volume (tKV) measured by MRI scanning | Between baseline and six weeks and between six and 12 weeks | The change in the total Kidney Volume after six and 12 weeks participation in the trial |
| Secondary | Changes in GFR | Between baseline and six weeks and between baseline and 12 weeks | The changes in GFR measured by Cr-EDTA clearance |
| Secondary | Changes in relevant genetic and non-genetic biomarkers associated with CKD and ESRD | Between baseline and six weeks and between baseline and 12 weeks | Prediction of change in progression of the disease over time in the genes PKD1, PKD2, PKHD1 and HNF1B. The following biomarkers will be determined: NGAL, UMOD, MCP-1, KIM-1, cystatin-C and copeptin |
| Secondary | Changes in Quality of Life | Between baseline and six weeks and between baseline and 12 weeks | Questionnaire SF36 Health Survey - with 36 questions to subject's health and wellbeing |
| Secondary | Subject estimation of own health | Between baseline and six weeks and between baseline and 12 weeks | Estimated by a Visual Analogue Scale from 0 (worth wellbeing) to 100 (best wellbeing |
| Secondary | Changes in ASAT and ALAT | Between baseline and six weeks and between baseline and 12 weeks | Changes estimated from laboratory results |
| Secondary | Incidence of Adverse Events | Between baseline and six weeks and between baseline and 12 weeks | Evaluation of Adverse Events including severity, causality, outcome and seriousness assessments |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03596957
GET https://conductscience.org/api/trials/v1/NCT03596957/registered